Trial Profile
(RICE) Plus Bortezomib (Velcade) in a Dose-Escalating Fashion for Patients With Relapsed or Primary Refractory Aggressive B-Cell NHL
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Carboplatin (Primary) ; Etoposide (Primary) ; Ifosfamide (Primary) ; Rituximab (Primary)
- Indications B-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- 01 Apr 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.